Please login to the form below

Addressing the Gendered Health Data Gap

The Women’s Health Strategy for England presents an opportunity to ensure that gendered inequalities in health data are recognised and addressed. Caroline Cirado Perez’s ‘Invisible Women’ highlights how women are missing from data sets leading to health interventions and technologies designed for men as the default. For example, women are 50% more likely to be misdiagnosed following a heart attack because participation in clinical trials is generally skewed towards males. In her latest blog, Hanover Health’s Emma Gorton outlines why data should form a key part of the Women’s Health Strategy to help address inequalities in outcomes for women.

When thinking about personalised treatment today, we think of targeted cancer treatments, or gene therapies. Treatments that are designed for small subgroups of diseases or people and which are more effective because they are designed specifically for what they intend to do.

Whilst we have made huge strides in improving treatment for some of these conditions, it seems we are still missing a trick. Without the need for technological advances or medical innovation, we could better design our health systems and our treatments for 50% of the patient population. It seems an obvious place to start.

Everything created in our world has been thought through in terms of design: how high to put the shelving units in the supermarket, the temperature of your office and the safety specifications of your car. In making these decisions engineers and designers look at data to understand the optimal approach.

However, this only works when the data is representative of the people the design is aiming to serve, and all too often it isn’t. Women are often underrepresented or missing from these data sets resulting in a world that has been designed for men as default. This is also true of our healthcare systems; our clinical trials, our diagnostic approaches and our treatment options, all typically have men as the default.

Take heart attacks for example, the British Heart Foundation found women are 50% more likely to be misdiagnosed following a heart attack. One of the routine tests to diagnose a heart attack is the troponin test used to identify damage to heart cells. However, it was found that the expected ‘normal’ limits set were those that were normal for men as the default, leading to a higher incidence of women’s heart attacks going misdiagnosed. Women were missing from the data sets used to build the limits, and therefore the test becomes much less effective for women.

By using a more sensitive test and altering the expected limits to be appropriate for women, the number of women diagnosed with a heart attack doubled – women who otherwise would not have received a diagnosis, leading to delay in treatment and therefore worse outcomes overall.

As Caroline Cirado Perez points out in her book Invisible Women, this isn’t some malicious attempt to exclude half of the population from the world we design, it is just a consequence of non-representation. By not including women in the data sets used we continue to build systems with men as the default and this can have serious, and potentially deadly, consequences.

However, as the example above shows, the potential for positive change can be huge. By simply splitting data sets by sex, we can quickly and easily identify missing data, and find opportunities where addressing these could make a big impact to addressing gendered health inequalities. If this had been done in setting heart attack limits it would have become clear that there should be different levels for men and women.

The WHO’s Global Health Statistics were disaggregated by sex for the first time in 2019. So, whilst it’s a wonder that this wasn’t considered before 2019, it’s a step in the right direction. It’s a starting line.

In the UK, the Government are looking to address gendered health inequalities, bringing forward England’s first Women’s Health Strategy. Putting aside the fact that even the need for this clearly shows that women’s health isn’t covered by ‘health’ in itself, it is a great opportunity to address the gendered health data gap.

As we start to put more and more faith in data, the responsibility to make sure this data is representative of both women and men becomes stronger. A key part of the Women’s Health Strategy should be on ensuring women are included in the data sets used in health system design, clinical trials and disease management and also that the data is disaggregated to identify gendered differences.

Disaggregating these data has clear benefits for the female 50% of the population but it also has benefits for other groups; race, ethnicity and socioeconomic factors should all be taken into account too.

Not only will this ensure we are designing systems for all the people that will use them, but it will also mean we are able to see solutions we wouldn’t otherwise and uncover things that don’t intuitively feel true, or that we or others would never think to consider. For example, despite pregnant women being at increased risk from COVID-19, it took a campaigning group for them to gain access to the vaccine, a result that benefits the health system as a whole. At a time when the health system is recovering from the COVID-19 pandemic, finding smart, effective solutions to improving the health of the nation is paramount.

It is fascinating to think of the breakthroughs we may be able to take in medicine simply by challenging ourselves to ask the right questions and look at the right data. All of us are designers in our everyday lives, whether designing disease awareness campaigns or creating policy asks. We can all take a better look at the insights and data we use to inform our decisions and design, but we should also feel buoyed by the impact that we can have in making the world one that works for everyone.

9th June 2021


Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Riverside House
Southwark Bridge House
United Kingdom

Latest content on this profile

What's next for the 'indispensable' health system?
No one is remotely indispensable” – those of the words many of us have heard these past few weeks. As Boris Johnson and the previously incumbent Cabinet are now considering their next moves, where does that leave health policy at one of the most volatile points in recent history? We were set for a bumper few months of hotly anticipated announcements, including the 10-Year Cancer  Plan response, the Women’s Health Strategy, and the implementation plan for the Life Sciences Vision, amongst many others. But what will happen as the forthcoming leadership contest dominates the column inches? How will the Civil Service and NHS stand up to the challenges it faces without certainty of who is steering the ship? We will explore some of the possibilities of what will happen next, and most importantly, how we in communications can support the health system at such a critical time post-pandemic. To find out, read the latest blog on the PM Hub, penned by Hanover Health's Senior Account Director Ursula Ritz.
Hanover Communications
How can the UK be a catalyst for change in women’s health? 
Women’s health has once again been thrust to the fore, with almost daily stories on hormone replacement therapy (HRT) supply shortages in the UK providing us with a stark reminder of the challenges women are facing in this country every day. The good news is, the UK Government is making a genuine and concerted effort to tackle women’s health issues, having set out its Vision for women’s health in December, and a full Strategy due to be published imminently. We have a real opportunity to change women’s experience of healthcare for the better, but we cannot afford to get this wrong. In her latest blog, Hanover’s Georgia Hunt explores how the upcoming Women’s Health Strategy should address the concerns of women today and improve the lives of the women of tomorrow.
Hanover Communications
Innovative contracting at the top of the market access agenda
Value-based contracting (VBC) is firmly on the market access agenda across Europe and there are converging views on what is needed in this space.  Pharma and biotech, patients, payers, regulators and HTA agencies gathered at the World Evidence, Pricing and Access Congress in March to discuss challenges and potential solutions. Hanover hosted a discussion about experiences of VBC and where changes are needed. We explored whether a global archetype approach could support in-country negotiating agreements.   In their latest blog, Hanover Health’s Emma Eatwell and Josie Godfrey explore what the future for VBC might look like.
Hanover Communications
The future of nanomedicine regulation
With the EU’s upcoming revision of the general pharmaceutical legislation, the bloc has the chance to provide long-awaited clarity around the future of nanomedicine. And just as important, it will give the EU a chance to lead on a conversation around the needed regulatory framework for nanomedicines as other countries -including the US- currently struggle with this. In their latest blog, Hanover Brussels Alicia Rojo Santos and Pilar Serrano explores why the sector expecting to set off following the success of the Pfizer and Moderna SARS-CoV-2 vaccines is more important than ever.
Hanover Communications
Getting it Right First Time: Building a Value-Based Contract Strategy
In their latest blog, Hanover Brussels Emma Eatwell and Josie Godfrey will explore how companies can efficiently and effectively increase the chances of securing value-based contracts that work for all.
Hanover Communications
The role of pharma in breaking through the backlog
As health systems emerge from the pandemic, and attention turns to the backlog of patients waiting for treatment, how can the pharmaceutical industry position itself as part of the solution? In his latest blog, Hanover Health’s Alexander Davies looks to answer the following questions – big pharma was there for the world when it needed vaccines in record-breaking time, can it find the innovations that we need now to clear through the queue of people waiting for treatment? Can it partner with health systems to speed up access, improve patient outcomes and reduce the burden on healthcare professionals? And, if it did so, what are the opportunities for its reputation?
Hanover Communications